Product Description
Exemestane is used to treat early and advanced breast cancer in women who have already stopped menstruating (postmenopausal). It is usually used in women who have already received a cancer medication called tamoxifen. Many breast cancer tumors grow in response to estrogen. (Sourced from: https://www.mayoclinic.org/drugs-supplements/exemestane-oral-route/side-effects/drg-20063757?p=1)
Mechanisms of Action: ARO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States, Unknown Location
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Bone Cancer|Granulosa Cell Tumor|Male Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2023-06524 | P2 |
Suspended |
Granulosa Cell Tumor |
2027-05-31 |
|
| ADEPT | P2 |
Recruiting |
Breast Cancer |
2026-09-01 |
|
| 2014-002114-23 | P2 |
Completed |
Bone Cancer|Breast Cancer |
2022-10-28 |
|
| BOLERO-5 | P2 |
Completed |
Breast Cancer |
2022-04-25 |